In vitro and in vivo synergy of MCP compounds with mitogen-activated protein kinase pathway- and microtubule-targeting inhibitors

Molecular Cancer Therapeutics

Volumn 6, Issue 3, 2007, Pages 898-906

  Skobeleva, Natalia ^a,b   Menon, Sanjay ^c,d   Weber, Lutz ^c   Golemis, Erica A ^a   Khazak, Vladimir ^c  

^a FOX CHASE CANCER CENTER   (United States)

^b PETERSBURG NUCLEAR PHYSICS INSTITUTE   (Russian Federation)

^c NexusPharma Inc   (United States)

^d BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; GEMCITABINE; MCP 110; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MONOCYTE CHEMOTACTIC PROTEIN 1; PACLITAXEL; PHOSPHOLIPASE A2 INHIBITOR; RAS PROTEIN; SORAFENIB; STAUROSPORINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; COLON CARCINOMA; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG POTENTIATION; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; KAPOSI SARCOMA; LUNG CARCINOMA; MAXIMUM TOLERATED DOSE; MICROTUBULE ASSEMBLY; MONOTHERAPY; MOUSE; NONHUMAN; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; REPEATED DRUG DOSE; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE; TUMOR XENOGRAFT;

3T3 CELLS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; COLONIC NEOPLASMS; DRUG SYNERGISM; ENZYME INHIBITORS; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, NUDE; MICE, SCID; MICROTUBULES; MITOGEN-ACTIVATED PROTEIN KINASES; PACLITAXEL; PROTO-ONCOGENE PROTEINS C-RAF; PROTO-ONCOGENE PROTEINS P21(RAS); SIGNAL TRANSDUCTION; TAXOIDS; TRANS-ACTIVATION (GENETICS); TUMOR CELLS, CULTURED; VINCRISTINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34147122159     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0602     Document Type: Article

References (46)

1. Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989; 49:4682-9.
2. Janes PW, Daly RJ, deFazio A, Sutherland RL. Activation of the Ras signalling pathway in human breast cancer cells overexpressing erbB-2. Oncogene 1994;9:3601-8.
3. Campbell PM, Der CJ. Oncogenic Ras and its role in tumor cell invasion and metastasis. Semin Cancer Biol 2004;14:105-14.
4. Cox AD, Der CJ. The dark side of Ras: regulation of apoptosis. Oncogene 2003;22:8999-9006.
5. Hamad NM, Elconin JH, Karnoub AE, et al. Distinct requirements for Ras oncogenesis in human versus mouse cells. Genes Dev 2002;16: 2045-57.
6. Kolch W. Ras/Raf signalling and emerging pharmacotherapeutic targets. Expert Opin Pharmacother 2002;3:709-18.
7. Kato-Stankiewicz J, Hakimi I, Zhi G, et al. Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells. Proc Natl Acad Sci U S A 2002;99:14398-403.
8. Lu Y, Sakamuri S, Chen Q-Z, et al. Solution phase parallel synthesis and evaluation of MAPK inhibitory activities of close structural analogues of a Ras pathway modulator. Bioorg Med Chem Lett 2004;14:3957-62.
9. Ihle NT, Paine-Murrieta G, Berggren MI, et al. The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts. Mol Cancer Ther 2005;4:1349-57.
10. Edwards LA, Verreault M, Thiessen B, et al. Combined inhibition of the phosphatidylinositol 3-kinase/Akt and Ras/mitogen-activated protein kinase pathways results in synergistic effects in glioblastoma cells. Mol Cancer Ther 2006;5:645-54.
11. Ciardiello F, De Vita F, Orditura M, Comunale D, Galizia G. Cetuximab in the treatment of colorectal cancer. Future Oncol 2005;1:173-81.
12. Pegram MD, Lipton A, Hayes DF, et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998;16:2659-71.
13. Plosker GL, Keam SJ. Spotlight on Trastuzumeb in the management of HER2-positive metastatic and early-stage breast cancer. BioDrugs 2006;20:259-62.
14. Montaner S, Sodhi A, Molinolo A, et al. Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi's sarcomagenesis and can promote the tumorigenic potential of viral latent genes. Cancer Cell 2003;3:23-36.
15. Mansour SJ, Matten WT, Hermann AS, et al. Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 1994;265:966-70.
16. Stanton VP, Jr., Nichols DW, Laudano AP, Cooper GM. Definition of the human raf amino-terminal regulatory region by deletion mutagenesis. Mol Cell Biol 1989;9:639-47.
17. Dadke D, Fryer BH, Golemis EA, Field J. Activation of p21-activated kinase 1-nuclear factor κB signaling by Kaposi's sarcoma-associated herpes virus G protein-coupled receptor during cellular transformation. Cancer Res 2003;63:8837-47.
18. Lyons JF, Wilhelm S, Hibner B, Bollag G. Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer 2001;8:219-25.
19. Cox AD, Der CJ. Biological assays for cellular transformation. Methods Enzymol 1994;238:277-94.
20. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
21. Gollob JA. Sorafenib: scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma. Clin Genitourin Cancer 2005;4:167-74.
22. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000;351:95-105.
23. Bhalla US, Ram PT, Iyengar R. MAP kinase phosphatase as a locus of flexibility in a mitogen-activated protein kinase signaling network. Science 2002;297:1018-23.
24. Mekhail TM, Markman M. Paclitaxel in cancer therapy. Expert Opin Pharmacother 2002;3:755-66.
25. Blagosklonny MV, Schulte T, Nguyen P, Trepel J, Neckers LM. Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. Cancer Res 1996;56:1851-4.
26. Blagosklonny MV, Giannakakou P, el-Deiry WS, et al. Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death. Cancer Res 1997;57:130-5.
27. Blagosklonny MV. Sequential activation and inactivation of G2 checkpoints for selective killing of p53-deficient cells by microtubule-active drugs. Oncogene 2002;21:6249-54.
28. Britten RA, Perdue S, Opoku J, Craighead P. Paclitaxel is preferentially cytotoxic to human cervical tumor cells with low Raf-1 kinase activity: implications for paclitaxel-based chemoradiation regimens. Radiother Oncol 1998;48:329-34.
29. Rasouli-Nia A, Liu D, Perdue S, Britten RA. High Raf-1 kinase activity protects human tumor cells against paclitaxel-induced cytotoxicity. Clin Cancer Res 1998;4:1111-6.
30. Britten RA, Perdue S, Eshpeter A, Merriam D. Raf-1 kinase activity predicts for paclitaxel resistance in TP53mut, but not TP53wt human ovarian cancer cells. Oncol Rep 2000;7:821-5.
31. Lee M, Koh WS, Han SS. Down-regulation of Raf-1 kinase is associated with paclitaxel resistance in human breast cancer MCF-7/Adr cells. Cancer Lett 2003;193:57-64.
32. Abal M, Andreu JM, Baresoain I. Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action. Curr Cancer Drug Targets 2003;3:193-203.
33. Ferlini C, Distefano M, Pignatelli F, et al. Antitumour activity of novel taxanes that act at the same time as cytotoxic agents and P-glycoprotein inhibitors. Br J Cancer 2000;83:1762-8.
34. Shields JM, Rogers-Graham K, Der CJ. Loss of transgelin in breast and colon tumors and in RIE-1 cells by Ras deregulation of gene expression through Raf-independent pathways. J Biol Chem 2002;277:9790-9.
35. Pruitt K, Pestell RG, Der CJ. Ras inactivation of the retinoblastoma pathway by distinct mechanisms in NIH 3T3 fibroblast and RIE-1 epithelial cells. J Biol Chem 2000;275:40916-24.
36. Hamden KE, Whitman AG, Ford PW, Shelton JG, McCubrey JA, Akula SM. Raf and VEGF: emerging therapeutic targets in Kaposi's sarcoma-associated herpesvirus infection and angiogenesis in hematopoietic and nonhematopoietic tumors. Leukemia 2005;19:18-26.
37. Hamden KE, Ford PW, Whitman AG, et al. Raf-induced vascular endothelial growth factor augments Kaposi's sarcoma-associated herpes-virus infection. J Virol 2004;78:13381-90.
38. Tulpule A, Groopman J, Saville MW, et al. Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma. Cancer 2002;95:147-54.
39. Bais C, Santomasso B, Coso O, et al. G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angio-genesis activator. Nature 1998;391:86-9.
40. Sodhi A, Montaner S, Patel V, et al. Akt plays a central role in sarcomagenesis induced by Kaposi's sarcoma herpesvirus-encoded G protein-coupled receptor. Proc Natl Acad Sci U S A 2004;101:4821-6.
41. Jazirehi AR, Vega MI, Chatterjee D, Goodglick L, Bonavida B. Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab. Cancer Res 2004;64:7117-26.
42. Cheung HW, Ling MT, Tsao SW, Wong YC, Wang X. Id-1-induced Raf/MEK pathway activation is essential for its protective role against Taxol-induced apoptosis in nasopharyngeal carcinoma cells. Carcinogenesis 2004;25:881-7.
43. O'Neill EE, Matallanas D, Kolch W. Mammalian sterile 20-like kinases in tumor suppression: an emerging pathway. Cancer Res 2005; 65:5485-7.
44. Carter CA, Chen C, Brink C, et al. Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma. Cancer Chemother Pharmacol 2007;59:183-95.
45. Figul M, Soling A, Dong HJ, Chou TC, Rainov NG. Combined effects of temozolomide and the ribonucleotide reductase inhibitors didox and trimidox in malignant brain tumor cells. Cancer Chemother Pharmacol 2003;52:41-6.
46. Reynolds CP, Maurer BJ. Evaluating response to antineoplastic drug combinations in tissue culture models. Methods Mol Med 2005;110: 173-83.